ABVC BioPharma Inc. is a clinical-stage biopharmaceutical company that identifies, in-licenses, and develops plant-derived compounds and medical devices to address unmet medical needs. It focuses on natural, plant-based medications targeting severe conditions in areas such as ophthalmology, central nervous system disorders, attention deficit hyperactivity disorder, depression, oncology, hematology, and more. Key pipeline candidates include ABV-1504 for major depressive disorder, which has completed Phase II trials; ABV-1505 for adult ADHD in Phase II; ABV-1701 Vitargus for retinal diseases in Phase II; and others like ABV-1501 for triple negative breast cancer, ABV-1702 for myelodysplastic syndromes, and ABV-1519 for non-small cell lung cancer, spanning Phase I/II to II trials. The company partners with global research institutions and seeks collaborations with large pharmaceutical firms for late-stage development and commercialization after Phase II success. Through its subsidiary BioKey, Inc., it provides contract development and manufacturing services for nutritional and pharmaceutical products. Founded in 2015 and headquartered in Fremont, California, ABVC BioPharma Inc. advances a growing portfolio supported by trials in multiple countries including the United States, Thailand, Australia, and Taiwan.